title: Tumour-initiating capacity is independent of epithelial-mesenchymal transition status in breast cancer cell lines.
abstract: BACKGROUND
  Epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs) are considered to be crucial for cancer biology. The purpose of this study was to determine whether EMT directly led to the acquisition of tumour-initiating capacity in breast cancer cell lines.
  
  
  METHODS
  Epithelial-mesenchymal transition was induced in five breast cancer cell lines and one normal breast cell line by EMT-related cytokine stimulation. Mesenchymal-epithelial transition (MET) was induced by stably overexpressing miR-200c in three mesenchymal-like breast cancer cell lines. Molecular expression and cell function analysis were performed to evaluate the effect of EMT or MET on tumour-initiating capacity and other biological characteristics.
  
  
  RESULTS
  The induction of EMT did not enhance tumour-initiating capacity but, instead, conferred a CD44(+)/CD24(-/low) phenotype as well as cell proliferation, migration, and resistance to doxorubicin and radiation on breast cancer cell lines. Furthermore, MET did not lead to inhibition or loss of the tumour-initiating capacity in mesenchymal-like breast cancer cell lines, but it markedly attenuated other malignant properties, including proliferation, invasion, and resistance to therapy.
  
  
  CONCLUSIONS
  Epithelial-mesenchymal transition does not alter tumour-initiating capacity of breast cancer cells but some other biological characteristics. Therefore, EMT and tumour-initiating capacity may not be directly linked in breast cancer cell lines.
authors.affiliation: Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, PR China.
authors.forename: G
authors.initials: G
authors.lastname: Xie
authors.affiliation: Department of Pharmaceutical Science, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, PR China.
authors.forename: A
authors.initials: A
authors.lastname: Ji
authors.affiliation: Jules Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
authors.forename: Q
authors.initials: Q
authors.lastname: Yuan
authors.affiliation: Department of Pharmacy, Jining First People's Hospital, Jining, Shandong 272111, PR China.
authors.forename: Z
authors.initials: Z
authors.lastname: Jin
authors.affiliation: Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, PR China.
authors.forename: Y
authors.initials: Y
authors.lastname: Yuan
authors.affiliation: Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, PR China.
authors.forename: C
authors.initials: C
authors.lastname: Ren
authors.affiliation: Breast Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, PR China.
authors.forename: Z
authors.initials: Z
authors.lastname: Guo
authors.affiliation: Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, PR China.
authors.forename: Q
authors.initials: Q
authors.lastname: Yao
authors.affiliation: Department of Neurosurgery, Institute of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, PR China.
authors.forename: K
authors.initials: K
authors.lastname: Yang
authors.affiliation: Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, PR China.
authors.forename: X
authors.initials: X
authors.lastname: Lin
authors.affiliation: Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, PR China.
authors.forename: L
authors.initials: L
authors.lastname: Chen
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000951:Antigens, Neoplasm / Q000032:analysis; D001943:Breast Neoplasms / Q000473:pathology*; D002455:Cell Division; D045744:Cell Line, Tumor; D002465:Cell Movement; D002772:Cholera Toxin / Q000494:pharmacology; D016207:Cytokines / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D058750:Epithelial-Mesenchymal Transition / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006801:Humans; D018960:Hyaluronan Receptors / Q000032:analysis; D006854:Hydrocortisone / Q000494:pharmacology; D016130:Immunophenotyping; D007328:Insulin / Q000494:pharmacology; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D035683:MicroRNAs / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology; D009368:Neoplasm Transplantation; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000502:physiology* / Q000528:radiation effects; D011836:Radiation Tolerance
chemical_list: D000903:Antibiotics, Antineoplastic; D000951:Antigens, Neoplasm; C497483:CD44 protein, human; D016207:Cytokines; D018960:Hyaluronan Receptors; D007328:Insulin; C533896:MIRN200 microRNA, human; D035683:MicroRNAs; D004317:Doxorubicin; D002772:Cholera Toxin; D006854:Hydrocortisone
references.citation: J Clin Invest. 2009 Jun;119(6):1438-49
references.pmid: 19487820
references.citation: Cancer Res. 2012 Jun 1;72(11):2889-900
references.pmid: 22505649
references.citation: Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
references.pmid: 12629218
references.citation: J Clin Invest. 2012 May;122(5):1849-68
references.pmid: 22505459
references.citation: Breast Cancer Res. 2010;12(5):R68
references.pmid: 20813035
references.citation: PLoS One. 2008 Aug 06;3(8):e2888
references.pmid: 18682804
references.citation: Cancer Cell. 2012 Dec 11;22(6):725-36
references.pmid: 23201165
references.citation: Dev Cell. 2004 Sep;7(3):425-38
references.pmid: 15363416
references.citation: Acta Anat (Basel). 1996;156(3):187-201
references.pmid: 9124036
references.citation: Cancer Res. 2013 Jul 1;73(13):4147-57
references.pmid: 23687336
references.citation: Cancer Res. 2013 Nov 15;73(22):6679-89
references.pmid: 24062311
references.citation: Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19035-9
references.pmid: 19858489
references.citation: Cell. 2008 May 16;133(4):704-15
references.pmid: 18485877
references.citation: Cancer Res. 2007 Apr 15;67(8):3691-7
references.pmid: 17440081
references.citation: Nature. 2005 Jul 28;436(7050):518-24
references.pmid: 16049480
references.citation: J Clin Invest. 2009 Jun;119(6):1420-8
references.pmid: 19487818
references.citation: Breast Cancer Res. 2011 Jun 10;13(3):211
references.pmid: 21672282
references.citation: J Natl Cancer Inst. 2006 Dec 20;98(24):1777-85
references.pmid: 17179479
references.citation: J Natl Cancer Inst. 2008 May 7;100(9):672-9
references.pmid: 18445819
references.citation: Int J Cancer. 2012 Sep 1;131(5):1023-31
references.pmid: 22038895
references.citation: Oncogene. 2009 Aug 20;28(33):2940-7
references.pmid: 19581928
references.citation: Curr Opin Genet Dev. 2004 Feb;14(1):43-7
references.pmid: 15108804
references.citation: Int J Oncol. 2012 Jun;40(6):1858-64
references.pmid: 22447278
references.citation: Cancer Res. 1990 Feb 1;50(3):717-21
references.pmid: 2297709
references.citation: Science. 2009 Jun 26;324(5935):1670-3
references.pmid: 19556499
references.citation: Mol Cancer. 2010 Jul 07;9:179
references.pmid: 20609236
references.citation: Cell Stem Cell. 2007 Nov;1(5):555-67
references.pmid: 18371393
references.citation: Nat Cell Biol. 2011 Mar;13(3):317-23
references.pmid: 21336307
references.citation: Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5
references.pmid: 19666588
references.citation: Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15735-40
references.pmid: 17898181
references.citation: J Biol Chem. 2013 Jun 21;288(25):17954-67
references.pmid: 23653350
references.citation: J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):235-52
references.pmid: 20521089
references.citation: Int J Cancer. 2009 Jan 1;124(1):36-45
references.pmid: 18844224
references.citation: Cell Res. 2009 Feb;19(2):156-72
references.pmid: 19153598
references.citation: BMC Cancer. 2013 Aug 12;13:383
references.pmid: 23937725
references.citation: Dev Cell. 2008 Jun;14(6):818-29
references.pmid: 18539112
references.citation: J Pathol. 2012 Oct;228(2):158-69
references.pmid: 22247069
references.citation: Genes Dev. 2008 Apr 1;22(7):894-907
references.pmid: 18381893
references.citation: Cancer Res. 2012 Sep 1;72(17):4597-608
references.pmid: 22787120
references.citation: Curr Opin Biotechnol. 2007 Oct;18(5):460-6
references.pmid: 18023337
references.citation: PLoS One. 2010 Aug 27;5(8):e12445
references.pmid: 20805998
references.citation: PLoS One. 2012;7(10):e47995
references.pmid: 23118918
references.citation: Cell. 2009 Nov 25;139(5):871-90
references.pmid: 19945376
references.citation: Br J Cancer. 2013 Oct 15;109(8):2248-58
references.pmid: 24045665
references.citation: Cell Cycle. 2012 Nov 1;11(21):4020-32
references.pmid: 22992620
references.citation: Oncogene. 2011 Nov 24;30(47):4707-20
references.pmid: 21602879
references.citation: Semin Cell Dev Biol. 2008 Jun;19(3):294-308
references.pmid: 18343170
references.citation: Development. 2008 Feb;135(3):579-88
references.pmid: 18192284
references.citation: Cancer Res. 2005 Jul 1;65(13):5506-11
references.pmid: 15994920
references.citation: Cancers (Basel). 2012 Mar 08;4(1):281-94
references.pmid: 24213240
references.citation: Nat Rev Cancer. 2009 Apr;9(4):265-73
references.pmid: 19262571
references.citation: Cancer Res. 2010 Dec 15;70(24):10433-44
references.pmid: 21159654
references.citation: Oncol Rep. 2009 Apr;21(4):995-1000
references.pmid: 19287999
references.citation: PLoS One. 2012;7(8):e41335
references.pmid: 22912670
references.citation: Am J Physiol Renal Physiol. 2006 May;290(5):F1202-12
references.pmid: 16368739
references.citation: Lab Invest. 2003 Mar;83(3):435-48
references.pmid: 12649344
references.citation: Nat Protoc. 2009;4(4):495-505
references.pmid: 19300443
references.citation: Curr Opin Oncol. 1997 Nov;9(6):549-56
references.pmid: 9370076